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1245 and 1253. Nearly 5 million Americans have heart failure (HF) today, with anincidence approaching 10 per 1000 population in persons olderthan 65 years of age; approximately 50% of these patients arewomen (Figure 1).1 In 2000, 62.3% of all HF mortalities occurredamong women; 20% of those patients died within 1 year of theirdiagnosis, and less than 15% of women survive more than 8 to 12
years after diagnosis.2 These results notwithstanding, the Framingham study re-
cently noted that the age-adjusted rates of HF are higher among men, with no
significant change in this rate over a 50-year period.3 Among women, the incidence
of HF has decreased by 31% to 40% in the decades after 1950.
HF is the reason for at least 20% of all hospital admissions in persons older than
65 years, and over the past decade, hospitalizations for HF have increased by 159%.
Women who have been hospitalized with HF have less improvement in physical
health status and perceive their quality of care to be lower than that of their male
cohorts.4 Of the thousands of patients disabled from HF within 6 years of their
diagnosis, 46% are adult women compared with only 22% of men. In 1997, an
estimated $5501 was spent for every hospital-discharge diagnosis of HF, and
another $1742 per month was required to care for each patient after discharge.
Gender has been shown to be an important determinant of hospital length of stay,
hospital charges, and mortality during hospitalization.5
The above statistics and countless other graphs, studies, and reports chronicle 2
very important issues: (1) the syndrome of HF has reached epidemic proportions in
the United States and throughout the world, and (2) the disease appears to have
different characteristics in men and women. It is reasonable to postulate that an
elucidation of these sex-specific differences might suggest novel approaches to the
prevention of this serious disorder. Moreover, additional insights into gender-
specific pathophysiologic mechanisms that lead to HF might be used to develop
unique therapies for this relentlessly lethal disease. This review, then, should be
regarded as more than a politically expedient exercise but as one part of the larger
battle to fight the syndrome of HF in all its forms. We would also like to
acknowledge the newer literature on this subject since the outstanding review of
Petrie and colleagues6 was published in 1999.
Epidemiology
Elderly patients in the United States represent an increasing proportion of patients
with HF. There is the general aging of the population, a progressive increase in the
age of onset of HF, and improved treatment of other cardiovascular diseases, such
as hypertension and myocardial infarction, to account for these figures.7 Although
the overall prevalence of HF is similar in men and women, there is a striking effect
of age on the prevalence of the disease. Men have a much higher prevalence of HF
when younger than 75 years of age, whereas women surpass the male prevalence
when older than 75 years of age. Importantly, these elderly female patients are much
more likely to have HF with preserved systolic function,8-11 or “diastolic heart
failure,” than their younger cohorts.7,12
Over the past 50 years, the incidence of HF has decreased among women but not
among men.3 What could account for this differing gender trend? Treatment of
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hypertension reduces the incidence of HF by about 50%,
and important advances have occurred in the awareness,
treatment, and control of high blood pressure during this
time period.13,14 The risk of HF imparted by hypertension is
greater for women than for men: the population-attributable
risk effect of hypertension was 59% in women and only
39% in men in an earlier Framingham report.15 Increasing
use of antihypertensive medications has led to a decrease in
the prevalence of high blood pressure and might have af-
fected the incidence of HF in women more so than in men.
In men the greater incidence of HF is partly explained by
the greater prevalence and incidence of arteriosclerosis and
coronary artery disease. Some data also suggest a sex dif-
ference in the cardiac response to increased afterload or
hypertension, as discussed subsequently.
Ventricular arrhythmias are thought to be caused by a
dispersion of normal conduction through nonhomogeneous
myocardial tissue, promoting repetitive ventricular rhythms.
The rate of sudden cardiac death among persons with HF is
6 to 9 times that seen in the general population16 and is more
common in men than in women.17 One study suggested that
women who present with sudden cardiac death are less
likely to have a prior history of heart disease than men (37%
vs 56%). More recent data revealed that women with car-
diac arrest are less likely than men to have ventricular
fibrillation as an initial rhythm.18 Albert and colleagues19
prospectively followed a cohort of 121,701 women aged 30
to 55 years at baseline and identified 244 cases of sudden
cardiac death between 1976 and 1998. Although the risk of
sudden death increased markedly as the women grew older,
the percentage of cardiac deaths that were sudden decreased
with age. Most (69%) women who had a sudden cardiac
death had no history of cardiac disease before their death,
but almost all (94%) of the women who died reported at
least 1 coronary risk factor. Smoking, hypertension, and
diabetes conferred a significantly increased risk of sudden
death similar to that seen in men.
Mortality From Heart Failure
There has been considerable scrutiny of a possible survival
advantage of women once they have HF in contrast to men.
Two large epidemiologic studies, Framingham20 and
NHANES-1,21 both reported an improved survival for
women, despite a greater average age in the female cohorts.
In contrast, the SOLVD investigators noted a worse out-
look, with a 1-year mortality rate of 22% in the women and
a 17% rate in the men of the study.22 All patients in SOLVD
had a formal measurement of left ventricular ejection frac-
tion (LVEF); entry into the large epidemiologic studies was
on the basis of symptoms without an assessment of LVEF.
Thus it is probable that the women followed in the earlier
studies had a higher incidence of diastolic HF as compared
with that in SOLVD, and this might account for their
survival advantage. Data from the Italian Network CHF
Registry, in which patients were enrolled on the basis of
signs and symptoms, reported a similar 1-year mortality in
men and women.23 However, the women of the cohort were
significantly older, had a worse functional class, and exhib-
ited a higher heart rate and systolic blood pressure with
more atrial fibrillation but less ventricular tachycardia. In
this study women were more likely to have preserved left
ventricular (LV) function than men.
It appears that the underlying cause of HF in women in
general is different than that in men, and these baseline risk
factors, outside the development of HF, might have an
important effect on prognosis. Diabetes, for example, is a
stronger risk factor for HF in women than in men, especially
in younger women.24 In a Framingham report increased
Figure 1. Prevalence and mortality of heart failure by gender: A, prevalence of heart failure in the United States,
1988 through 1994, by age group and gender; B, mortality (51,546 total deaths, including Hispanics) in 2000.
Percentage of male deaths was 37.6%, and percentage of female deaths was 62.4%.1
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wall thickness and LV mass were found in women but not
in men with diabetes mellitus.25 Moreover, LV mass and
wall thickness increases with worsening glucose intoler-
ance, an effect that is also more striking in women.26 Thus
if one were to examine a given population of patients with
HF, the women in the group would more likely be older,
have diabetes, and have hypertension. Age, hypertension,
and diabetes are powerful determinants of prognosis in
other cardiovascular disorders, such as in patients after
myocardial infarction or cardiac surgery, and women fre-
quently do less well because of these additional risk factors.
Why is it that women with the same comorbid conditions
and HF fare better than their male counterparts?
Mortality outcomes become even more muddled as the
large randomized clinical trials are examined with regard to
this issue. As mentioned earlier, women survived less fre-
quently in SOLVD, a study of patients with LV systolic
dysfunction.22 In the FIRST study, which involved patients
with far-advanced systolic dysfunction and refractory symp-
toms, only women without ischemic heart disease had a
better prognosis compared with the prognosis of the male
patients.27 However, in 2 large trials studying patients with
systolic dysfunction and symptomatic HF, MERIT-HF28
and CIBIS-II,29 women had a significantly improved sur-
vival, even after adjustment for baseline differences, includ-
ing -blocker treatment and ischemic cause. The mecha-
nisms that determine an enhanced survival for women with
HF require elucidation.
Pathophysiology
Numerous studies have shown that the clinical manifesta-
tions and prognosis of women with ischemic heart disease
differ significantly from those of men. In spite of having
preserved LV systolic function more often than men,
women have more symptoms of HF.30-32 Mendes and col-
leagues33 sought to understand more completely the rela-
tionship between sex and LV pressure and volume in pa-
tients referred for cardiac catheterization. Women
comprised 35% of the 1667 patients undergoing catheter-
ization. They also had a higher prevalence of hypertension
(41% in women and 31% in men), diabetes (18% in women
and 12% in men), and HF (13% in women and 10% in men).
At the time of the procedure, women had a higher LVEF,
61% compared with the men’s 56%, but had less 3-vessel
Figure 2. Gender-related survival rates and how they might be influenced by different pathophysiologic mecha-
nisms in men and women. LV, Left ventricle; LVH, left ventricular hypertrophy; RAS, renin-angiotensin system; SNS,
sympathetic nervous system.









CONSENSUS-I39 253 75 30
SOLVD-T40 2569 504 23
SOLVD-P41 4228 476 31
ELITE-I42 722 240 31
ELITE-II43 3152 966 30
MERIT-HF44 3991 451 23
CIBIS II45 2647 515 20
COPERNICUS46 2287 465 28
BEST47 2708 593 22
Val HEFT48 5010 1002 20
RALES49 1663 446 27
SAVE50 2231 390 28
TRACE51 1749 501 22
CHARM52 7599 243 32
SCD HeFT53 2521 580 23
DIG54 6800 1520 22.4
TOTAL 50,130 11,500 23
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coronary disease. In a multivariate analysis female sex
remained an independent predictor of HF. The LV end-
diastolic volume index was smaller in women despite a
similar LV end-diastolic pressure. When patients were strat-
ified according to LV end-diastolic pressure, women had a
significantly smaller end-diastolic volume. The authors sug-
gested that the response of the left ventricle to the pressure-
overload state, such as that seen in hypertension, might be
modified by sex. The pressure-volume relationship noted in
the study by Mendes and colleagues33 accounts for the
diastolic abnormalities seen so often in women with HF and
explains the degree of symptoms despite a preserved LVEF.
Other pathophysiologic differences exist in patients with
HF that appear to be sex determined. Aronson and Burger34
examined heart rate variability in patients with nonischemic
HF and found that women have attenuated sympathetic acti-
vation and an attenuated parasympathetic withdrawal. Current
understanding about the critical role of the sympathetic ner-
vous system in the progression of HF suggests that the above
findings might be advantageous. Likewise, investigators have
shown that myocyte necrosis and apoptosis are significantly
reduced in women with HF, despite a longer duration of
disease compared with that seen in the men in the study
populations.35 There are also considerable data to conclude
that gender and sex hormones affect the components of the
renin-angiotensin system through a number of mechanisms.36
Figure 2 depicts a possible schema of the pathophysio-
logic response to myocardial injury in men and women
derived in part from the above and other studies. The clinical
observation that women present with symptoms of HF later in
life with more concentric LV hypertrophy might be explained
by a gender-specific tendency that confers an improved sur-
vival in many instances. Recent reports suggest that the gender
response to postinfarction injury favors women in that they
have less hypertrophy, a pattern quite different than that ob-
served in nonischemic cardiomyopathy.37
Management of Heart Failure
Our ability to discern whether women respond to pharmaco-
therapy for HF in a meaningfully dissimilar manner from men
has been impaired by the failure to enroll adequate numbers of
women into many of the HF trials, as shown in Table 1.38-54 To
be fair, this low enrollment rate is probably caused, in part, by
a greater proportion of diastolic HF in women, making them
ineligible for the trials outlined in Table 1.55
Women might receive less optimal care for a variety of
reasons. Harjai and coworkers56 showed that, even after
adjusting for age, race, coronary artery disease, and LVEF,
there was a higher use of combination therapy by cardiol-
ogists in male versus female patients. Improvements in peak
exercise capacity might be more pronounced in men than in
women with HF after exercise training, and yet women are
referred less often to cardiac rehabilitation.57 In addition,
the skeletal muscle abnormalities described in the legs of
male patients with HF are not as pronounced in women.58
Women had more side effects in the SOLVD trial.59 Most
important, however, is the lack of definitive randomized
trials in patients with diastolic HF, a group of patients who
are predominantly women.60 Some of the differences be-
tween men and women at baseline when enrolled in clinical
trials are shown in Table 2. 22,27-29,61 Note the greater
degree of hypertension and diabetes in women.22,27-29,61,62
In summary, there is mounting evidence that there are
important sex differences in the phenotype of HF as we
understand it currently. Women appear to have an overall
improved outlook once they become symptomatic with HF.
The mechanisms behind this advantage are worthy of fur-
ther exploration.
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